Biologics
Biologics

Polatuzumab vedotin ,Polivy ,CD79B ,RG7596 ,ADC ,CD79b-targeted therapy ,Microtubule inhibitor ,Oncology ADC / DLBCL ADC / Lymphoma ADC ,Intravenous infusion ,CAS No.1313206-42-6

Polatuzumab vedotin ,Polivy ,CD79B ,RG7596 ,ADC ,CD79b-targeted therapy ,Microtubule inhibitor ,Oncology ADC / DLBCL ADC / Lymphoma ADC ,Intravenous infusion ,CAS No.1313206-42-6
Trade Name
Polivy
Target
CD79B
Molecular Type
ADC
Sales In 2025 (Millions Of USD)
850(First Half Of The Year)
Product Summary

Trade Name : PolivyTarget : CD79BMolecular Type : ADCSales in 2025 (Millions of USD) : 850(First half of the year)All detailed product information shall be subject to the issued final COA.Should you need further in-depth documentation for this item, kindly get in touch with us.

Product Description
Detailed Specifications & Features

Trade Name : Polivy
Target : CD79B
Molecular Type : ADC
Sales in 2025 (Millions of USD) : 850(First half of the year)
All detailed product information shall be subject to the issued final COA.
Should you need further in-depth documentation for this item, kindly get in touch with us.